Alzheimer's definition what solution ?

One of the most important worldwide challenges are the next generation Alzheimer's disease treatments. New results, candidate therapeutics, and methodological issues will be some of the major worldwide issues discussed at the 2019 CTAD Congress. Alzheimer's disease symptoms and dementia treatment will be dealt with at the CTAD 2019 Congress. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Tau Biomarkers was proved to be one of the therapeutics combination as shown in the phase 43 clinical trials results. Studies on the early stage symptoms will be presented at the 2019 CTAD Congress by the clinical teams. New examples of trials will be highlighted in the 2019 CTAD Congress. Speeding the development of effective Alzheimer's treatment disease is one of the urge of the CTAD 2019 conference. Reviews, original research articles and short reports on Alzheimer prevention will be published in the JPAD . They will include articles on the following topics : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.